여행자 설사증(TD) : 시장 전망, 역학, 경쟁 구도, 시장 예측 보고서(2026-2036년)

Traveler's Diarrhea Market Outlook and Forecast

Thelansis's "Traveler's Diarrhea (TD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2026 To 2036" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Traveler's Diarrhea treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Traveler's Diarrhea Overview

Traveler's diarrhea (TD) is an acute infectious GI syndrome caused by enteric pathogens including Escherichia coli, Campylobacter, Shigella, Salmonella, norovirus, and parasites. Symptoms range from mild loose stools to severe diarrhea with abdominal pain, fever, vomiting, and dehydration; persistent cases may cause post-infectious symptoms. Management centers on oral rehydration and symptom control, with antibiotics mainly reserved for moderate or severe illness. Azithromycin is preferred for severe or dysenteric illness, while rifaximin and rifamycin SV are options for selected noninvasive bacterial infections. Routine antibiotic prophylaxis is generally discouraged because of adverse effects and antimicrobial-resistance risks. Development is shifting toward pathogen-specific prevention and microbiome-sparing strategies, including oral vaccines targeting enteric pathogens. Key opportunities remain in prevention, resistance reduction, and convenient protection for high-risk travelers.

Key Highlights

• In Germany, diagnosed Traveler's Diarrhea (TD) cases are projected to increase from 3,265,903 in 2026 to 4,303,734 by 2036.
• TD is a common gastrointestinal infection associated with contaminated food and water during travel.
• Disease burden is influenced by travel exposure, sanitation, and regional infection risks.
• Unmet need remains for effective prevention and treatment, particularly for drug-resistant infections.

Market Overview

• The France TD market is projected to grow from $35M in 2026 to $65M by 2036.
• Market growth is driven by:
• Rising international travel and disease awareness
• Increasing need for effective anti-infective and preventive therapies
• Future growth will depend on improved prevention and treatments for resistant or persistent infections.

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2026-2036)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets, etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key current therapies - profiles and KOL insights
• Emerging therapies
• Key takeaways
• Notable late-phase emerging therapies - profiles, launch expectations, KOL insights
• Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)